Chemomab Therapeutics Ltd. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Chemomab Therapeutics Ltd. (CMMB) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $9.04 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-23.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-23
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | $9.04M 20-F · filed 2026-03-23 |
| 2024-12-31 | $13.93M 20-F · filed 2026-03-23 |
| 2023-12-31 | $23.53M 20-F · filed 2026-03-23 |